CNO FINANCIAL GROUP, INC., 10-K filed on 2/26/2019
Annual Report
v3.10.0.1
DOCUMENT AND ENTITY INFORMATION - USD ($)
$ in Billions
12 Months Ended
Dec. 31, 2018
Feb. 08, 2019
Jun. 30, 2018
Document and Entity Information [Abstract]      
Entity Registrant Name CNO Financial Group, Inc.    
Entity Central Index Key 0001224608    
Document Type 10-K    
Document Period End Date Dec. 31, 2018    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2018    
Document Fiscal Period Focus FY    
Entity Filer Category Large Accelerated Filer    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer Yes    
Entity Current Reporting Status Yes    
Amendment Flag false    
Entity Public Float     $ 3.1
Entity Common Stock, Shares Outstanding   160,715,150  
Entity Emerging Growth false    
Entity Small Business false    
Entity Shell Company false    
v3.10.0.1
CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Dec. 31, 2018
Dec. 31, 2017
Investments:    
Fixed maturities, available for sale, at fair value (amortized cost: 2018 - $18,107.8; 2017 - $20,702.1) $ 18,447.7 $ 22,910.9
Equity securities at fair value (cost: 2018 - $319.8; 2017 - $420.0) 291.0 440.6
Mortgage loans 1,602.1 1,650.6
Policy loans 119.7 116.0
Trading securities 233.1 284.6
Investments held by variable interest entities 1,468.4 1,526.9
Other invested assets 833.4 924.5
Total investments 22,995.4 27,854.1
Cash and cash equivalents - unrestricted 594.2 578.4
Cash and cash equivalents held by variable interest entities 62.4 178.9
Accrued investment income 205.2 245.9
Present value of future profits 343.6 359.6
Deferred acquisition costs 1,322.5 1,026.8
Reinsurance receivables 4,925.4 2,175.2
Income tax assets, net 630.0 366.9
Assets held in separate accounts 4.4 5.0
Other assets 356.7 319.5
Total assets 31,439.8 33,110.3
Liabilities for insurance products:    
Policyholder account balances 11,594.1 11,220.7
Future policy benefits 11,082.4 11,521.3
Liability for policy and contract claims 521.9 530.3
Unearned and advanced premiums 253.9 261.7
Liabilities related to separate accounts 4.4 5.0
Other liabilities 632.4 751.8
Investment borrowings 1,645.8 1,646.7
Borrowings related to variable interest entities 1,417.2 1,410.7
Notes payable – direct corporate obligations 916.8 914.6
Total liabilities 28,068.9 28,262.8
Commitments and Contingencies
Shareholders' equity:    
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2018 - 162,201,692; 2017 - 166,857,931) 1.6 1.7
Additional paid-in capital 2,995.0 3,073.3
Accumulated other comprehensive income 177.7 1,212.1
Retained earnings 196.6 560.4
Total shareholders' equity 3,370.9 4,847.5
Total liabilities and shareholders' equity $ 31,439.8 $ 33,110.3
v3.10.0.1
CONSOLIDATED BALANCE SHEET (Parentheticals) - USD ($)
$ in Millions
Dec. 31, 2018
Dec. 31, 2017
Investments:    
Fixed maturities, available for sale, amortized cost $ 18,107.8 $ 20,702.1
Equity securities cost $ 319.8 $ 420.0
Shareholders' equity:    
Common stock, par value (in USD per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 8,000,000,000 8,000,000,000
Common stock, shares issued (in shares) 162,201,692 166,857,931
Common stock, shares outstanding (in shares) 162,201,692 166,857,931
v3.10.0.1
CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Revenues:      
Insurance policy income $ 2,593.1 $ 2,647.3 $ 2,601.1
Net investment income:      
General account assets 1,279.7 1,285.4 1,204.1
Policyholder and other special-purpose portfolios 26.5 265.9 121.1
Realized investment gains (losses):      
Net realized gains on the transfer of assets related to reinsurance transaction 363.4 0.0 0.0
Other net realized investment gains, excluding impairment losses (8.7) 77.4 47.9
Other-than-temporary impairments:      
Total other-than-temporary impairment losses (2.6) (21.9) (35.9)
Portion of other-than-temporary impairment losses recognized in accumulated other comprehensive income 0.0 (0.9) 3.6
Net impairment losses recognized (2.6) (22.8) (32.3)
Loss on dissolution of variable interest entities 0.0 (4.3) (7.3)
Total realized gains 352.1 50.3 8.3
Fee revenue and other income 62.1 48.3 50.5
Total revenues 4,313.5 4,297.2 3,985.1
Benefits and expenses:      
Insurance policy benefits 2,278.6 2,602.7 2,390.5
Loss related to reinsurance transactions 1,067.6 0.0 75.4
Interest expense 149.8 123.7 116.4
Amortization 264.3 239.3 253.3
Loss on extinguishment of borrowings related to variable interest entities 3.8 9.5 0.0
Other operating costs and expenses 814.2 841.5 796.3
Total benefits and expenses 4,578.3 3,816.7 3,631.9
Income (loss) before income taxes (264.8) 480.5 353.2
Income tax expense (benefit):      
Tax expense (benefit) on period income (57.6) 162.8 127.8
Valuation allowance for deferred tax assets and other tax items 107.8 142.1 (132.8)
Net income (loss) $ (315.0) $ 175.6 $ 358.2
Basic:      
Weighted average shares outstanding (in shares) 165,457 170,025 176,638
Net income (in USD per share) $ (1.90) $ 1.03 $ 2.03
Diluted:      
Weighted average shares outstanding (in shares) 165,457 172,144 178,323
Net income (loss) (in USD per share) $ (1.90) $ 1.02 $ 2.01
v3.10.0.1
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Statement of Comprehensive Income [Abstract]      
Net income (loss) $ (315.0) $ 175.6 $ 358.2
Other comprehensive income, before tax:      
Unrealized gains (losses) for the period (1,579.9) 959.3 424.4
Amortization of present value of future profits and deferred acquisition costs 125.5 (29.7) (27.9)
Amount related to premium deficiencies assuming the net unrealized gains (losses) had been realized 512.0 (310.5) (46.9)
Reclassification adjustments:      
For net realized investment gains (losses) included in net income (loss) (356.9) (40.2) (18.6)
For amortization of the present value of future profits and deferred acquisition costs related to net realized investment gains (losses) included in net income (loss) (0.4) 1.0 0.7
Unrealized gains (losses) on investments (1,299.7) 579.9 331.7
Change related to deferred compensation plan 0.0 0.0 8.6
Other comprehensive income (loss) before tax (1,299.7) 579.9 340.3
Income tax (expense) benefit related to items of accumulated other comprehensive income (loss) 281.6 (195.6) (120.7)
Other comprehensive income (loss), net of tax (1,018.1) 384.3 219.6
Comprehensive income (loss) $ (1,333.1) $ 559.9 $ 577.8
v3.10.0.1
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Common stock and additional paid-in capital
Accumulated other comprehensive income
Retained earnings
Balance, beginning of period at Dec. 31, 2015 $ 4,138.5 $ 3,388.6 $ 402.8 $ 347.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) 358.2     358.2
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense (benefit)) 221.1   221.1  
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense (benefit)) (1.5)   (1.5)  
Cost of common stock repurchased (203.0) (203.0)    
Dividends on common stock (54.6)     (54.6)
Stock options, restricted stock and performance units 28.2 28.2    
Balance, end of period at Dec. 31, 2016 4,486.9 3,213.8 622.4 650.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) 175.6     175.6
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense (benefit)) 382.1   382.1  
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense (benefit)) 2.2   2.2  
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act     205.4 (205.4)
Cost of common stock repurchased (167.1) (167.1)    
Dividends on common stock (59.9)     (59.9)
Stock options, restricted stock and performance units 27.4 27.4    
Balance, end of period at Dec. 31, 2017 4,847.5 3,075.0 1,212.1 560.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) (315.0)     (315.0)
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense (benefit)) (1,017.0)   (1,017.0)  
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense (benefit)) (1.1)   (1.1)  
Cost of common stock repurchased (100.9) (100.9)    
Dividends on common stock (65.1)     (65.1)
Stock options, restricted stock and performance units 22.5 22.5    
Balance, end of period at Dec. 31, 2018 $ 3,370.9 $ 2,996.6 $ 177.7 $ 196.6
v3.10.0.1
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Parentheticals) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Statement of Stockholders' Equity [Abstract]      
Change in unrealized appreciation (depreciation) of investments, applicable income tax expense (benefit) $ (281.3) $ 194.4 $ 121.5
Change in noncredit component of impairment losses on fixed maturities, available for sale, applicable income tax expense (benefit) $ (0.3) $ 1.2 $ (0.8)
v3.10.0.1
CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:      
Insurance policy income $ 2,433.4 $ 2,483.2 $ 2,457.0
Net investment income 1,321.2 1,256.3 1,213.9
Fee revenue and other income 62.1 48.3 50.5
Cash and cash equivalents received upon recapture of reinsurance 0.0 0.0 73.6
Insurance policy benefits (1,910.7) (1,973.1) (1,916.0)
Payment to reinsurer pursuant to long-term care business reinsured (365.0) 0.0 0.0
Interest expense (141.1) (120.5) (106.0)
Deferrable policy acquisition costs (261.8) (236.1) (242.7)
Other operating costs (788.5) (747.4) (747.9)
Income taxes (31.8) (77.4) (6.7)
Net cash from operating activities 317.8 633.3 775.7
Cash flows from investing activities:      
Sales of investments 3,210.2 2,460.7 2,828.9
Maturities and redemptions of investments 2,469.0 3,324.6 2,507.2
Purchases of investments (6,205.8) (6,141.0) (6,159.8)
Net sales (purchases) of trading securities 25.9 108.9 (84.2)
Other (25.0) (23.4) (22.5)
Net cash used by investing activities (525.7) (270.2) (930.4)
Cash flows from financing activities:      
Issuance of common stock 3.9 8.3 8.4
Payments to repurchase common stock (108.0) (168.3) (210.0)
Common stock dividends paid (64.8) (59.6) (54.8)
Amounts received for deposit products 1,588.5 1,445.9 1,386.7
Withdrawals from deposit products (1,312.3) (1,232.6) (1,181.6)
Issuance of investment borrowings:      
Federal Home Loan Bank 150.0 432.0 432.7
Related to variable interest entities 277.6 981.6 493.2
Payments on investment borrowings:      
Federal Home Loan Bank (150.9) (432.7) (333.5)
Related to variable interest entities and other (276.8) (1,248.6) (514.9)
Net cash provided (used) by financing activities 107.2 (274.0) 26.2
Net increase (decrease) in cash and cash equivalents (100.7) 89.1 (128.5)
Cash and cash equivalents - unrestricted and held by variable interest entities, beginning of year 757.3 668.2 796.7
Cash and cash equivalents - unrestricted and held by variable interest entities, end of year $ 656.6 $ 757.3 $ 668.2
v3.10.0.1
BUSINESS AND BASIS OF PRESENTATION
12 Months Ended
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS AND BASIS OF PRESENTATION
BUSINESS AND BASIS OF PRESENTATION

CNO Financial Group, Inc., a Delaware corporation ("CNO"), is a holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products.  The terms "CNO Financial Group, Inc.", "CNO", the "Company", "we", "us", and "our" as used in these financial statements refer to CNO and its subsidiaries.  Such terms, when used to describe insurance business and products, refer to the insurance business and products of CNO's insurance subsidiaries.

We focus on serving middle-income pre-retiree and retired Americans, which we believe are attractive, underserved, high growth markets.  We sell our products through three distribution channels: career agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; long-term care in run-off; and corporate operations, comprised of holding company activities and certain noninsurance company businesses. On September 27, 2018, the Company completed a long-term care reinsurance transaction pursuant to which its wholly-owned subsidiary, Bankers Life and Casualty Company ("Bankers Life"), entered into an agreement with Wilton Reassurance Company ("Wilton Re") to cede all of its legacy (prior to 2003) comprehensive and nursing home long-term care policies (with statutory reserves of $2.7 billion) through 100% indemnity coinsurance, as further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance". In anticipation of the reinsurance agreement, the Company reorganized its business segments to move the block to be ceded from the "Bankers Life segment" to the "Long-term care in run-off segment" in the third quarter of 2018. All prior period segment disclosures have been revised to conform to management's current view of the Company's operating segments.

Bankers Life, which underwrites, markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices.  The Bankers Life segment includes primarily the business of Bankers Life.  Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plan products in exchange for a fee.

Washington National, which underwrites, markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite.  These products are marketed through Performance Matters Associates, Inc. and through independent marketing organizations and insurance agencies including worksite marketing.  The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.

Colonial Penn, which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing.  The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn").

Long-term care in run-off consists of: (i) the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016 (such business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC"); and (ii) certain legacy (prior to 2003) comprehensive and nursing home long-term care policies which were ceded in September 2018 (such business is not actively marketed and was issued by Bankers Life).

We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP"). We have reclassified certain amounts from the prior periods to conform to the 2018 presentation. These reclassifications have no effect on net income or shareholders' equity.

The accompanying financial statements include the accounts of the Company and its subsidiaries. Our consolidated financial statements exclude transactions between us and our consolidated affiliates, or among our consolidated affiliates.

When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods.  For example, we use significant estimates and assumptions to calculate values for deferred acquisition costs, the present value of future profits, fair value measurements of certain investments (including derivatives), other-than-temporary impairments of investments, assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation and guaranty fund assessment accruals.  If our future experience differs from these estimates and assumptions, our financial statements would be materially affected.
v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Investments

Fixed maturity securities include available for sale bonds and redeemable preferred stocks. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders’ equity.
Equity securities include investments in common stock, exchange-traded funds and non-redeemable preferred stock. We carry these investments at estimated fair value. Effective January 1, 2018, changes in the fair value of equity securities are recognized in net income as further described below under the caption "Recently Issued Accounting Standards - Adopted Accounting Standards". Prior to January 1, 2018, changes in the fair value of equity securities were recorded in "Accumulated other comprehensive income".

Mortgage loans held in our investment portfolio are carried at amortized unpaid balances, net of provisions for estimated losses. Interest income is accrued on the principal amount of the loan based on the loan's contractual interest rate. Payment terms specified for mortgage loans may include a prepayment penalty for unscheduled payoff of the investment. Prepayment penalties are recognized as investment income when received.

Policy loans are stated at current unpaid principal balances. Policy loans are collateralized by the cash surrender value of the life insurance policy. Interest income is recorded as earned using the contractual interest rate.

Trading securities include: (i) investments purchased with the intent of selling in the near team to generate income; (ii) investments supporting certain insurance liabilities; and (iii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. The change in fair value of the income generating investments and investments supporting insurance liabilities and reinsurance agreements is recognized in income from policyholder and other special-purpose portfolios (a component of net investment income). The change in fair value of securities with embedded derivatives is recognized in realized investment gains (losses). Investment income related to investments supporting certain insurance liabilities is substantially offset by the change in insurance policy benefits related to certain products.

Other invested assets include: (i) call options purchased in an effort to offset or hedge the effects of certain policyholder benefits related to our fixed index annuity and life insurance products; (ii) Company-owned life insurance ("COLI"); (iii) investments in the common stock of the Federal Home Loan Bank ("FHLB"); and (iv) certain non-traditional investments. We carry the call options at estimated fair value as further described in the section of this note entitled "Accounting for Derivatives". We carry COLI at its cash surrender value which approximates its net realizable value. Non-traditional investments include investments in certain limited partnerships and hedge funds which are accounted for using the equity method; and promissory notes, which are accounted for using the cost method. In accounting for limited partnerships and hedge funds, we consistently use the most recently available financial information provided by the general partner or manager of each of these investments, which is one to three months prior to the end of our reporting period.

Interest income on fixed maturity securities is recognized when earned using a constant effective yield method giving effect to amortization of premiums and accretion of discounts. Prepayment fees are recognized when earned. Dividends on equity securities are recognized when declared.
When we sell a security (other than trading securities), we report the difference between the sale proceeds and amortized cost (determined based on specific identification) as a realized investment gain or loss.

We regularly evaluate our investments for possible impairment as further described in the note to the consolidated financial statements entitled "Investments".

When a security defaults (including mortgage loans) or securities are other-than-temporarily impaired, our policy is to discontinue the accrual of interest and eliminate all previous interest accruals, if we determine that such amounts will not be ultimately realized in full.
Cash and Cash Equivalents

Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value. It is the Company's policy to offset negative cash balances with positive balances in other accounts with the same counterparty when agreements are in place permitting legal right of offset.
Deferred Acquisition Costs

Deferred acquisition costs represent incremental direct costs related to the successful acquisition of new or renewal insurance contracts. For interest-sensitive life or annuity products, we amortize these costs in relation to the estimated gross profits using the interest rate credited to the underlying policies. For other products, we amortize these costs in relation to future anticipated premium revenue using the projected investment earnings rate.

When we realize a gain or loss on investments backing our interest-sensitive life or annuity products, we adjust the amortization to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We also adjust deferred acquisition costs for the change in amortization that would have been recorded if our fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We limit the total adjustment related to the impact of unrealized losses to the total of costs capitalized plus interest related to insurance policies issued in a particular year. We include the impact of this adjustment in accumulated other comprehensive income (loss) within shareholders' equity.

We regularly evaluate the recoverability of the unamortized balance of the deferred acquisition costs. We consider estimated future gross profits or future premiums, expected mortality or morbidity, interest earned and credited rates, persistency and expenses in determining whether the balance is recoverable. If we determine a portion of the unamortized balance is not recoverable, it is charged to amortization expense. In certain cases, the unamortized balance of the deferred acquisition costs may not be deficient in the aggregate, but our estimates of future earnings indicate that profits would be recognized in early periods and losses in later periods. In this case, we increase the amortization of the deferred acquisition costs over the period of profits, by an amount necessary to offset losses that are expected to be recognized in the later years.
Present Value of Future Profits

The present value of future profits is the value assigned to the right to receive future cash flows from policyholder insurance contracts existing at September 10, 2003 (the "Effective Date", the effective date of the bankruptcy reorganization of Conseco, Inc., an Indiana corporation (our "Predecessor")). The discount rate we used to determine the present value of future profits was 12 percent. The balance of this account is amortized and evaluated for recovery in the same manner as described above for deferred acquisition costs.  We also adjust the present value of future profits for the change in amortization that would have been recorded if the fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields, similar to the manner described above for deferred acquisition costs.  We limit the total adjustment related to the impact of unrealized losses to the total present value of future profits plus interest.
Recognition of Insurance Policy Income and Related Benefits and Expenses on Insurance Contracts

For interest-sensitive life and annuity contracts that do not involve significant mortality or morbidity risk, the amounts collected from policyholders are considered deposits and are not included in revenue. Revenues for these contracts consist of charges for policy administration, cost of insurance charges and surrender charges assessed against policyholders' account balances. Such revenues are recognized when the service or coverage is provided, or when the policy is surrendered.

We establish liabilities for annuity and interest-sensitive life products equal to the accumulated policy account values, which include an accumulation of deposit payments plus credited interest, less withdrawals and the amounts assessed against the policyholder through the end of the period. In addition, policyholder account values for certain interest-sensitive life products are impacted by our assumptions related to changes of certain non-guaranteed elements that we are allowed to make under the terms of the policy, such as cost of insurance charges, expense loads, credited interest rates and policyholder bonuses. Sales inducements provided to the policyholders of these products are recognized as liabilities over the period that the contract must remain in force to qualify for the inducement. The options attributed to the policyholder related to our fixed index annuity products are accounted for as embedded derivatives as described in the section of this note entitled "Accounting for Derivatives".

Premiums from individual life products (other than interest-sensitive life contracts) and health products are recognized when due. When premiums are due over a significantly shorter period than the period over which benefits are provided, any gross premium in excess of the net premium (i.e., the portion of the gross premium required to provide for all expected future benefits and expenses) is deferred and recognized into revenue in a constant relationship to insurance in force. Benefits are recorded as an expense when they are incurred.

We establish liabilities for traditional life, accident and health insurance, and life contingent payment annuity products using mortality tables in general use in the United States, which are modified to reflect the Company's actual experience when appropriate. We establish liabilities for accident and health insurance products using morbidity tables based on the Company's actual or expected experience. These reserves are computed at amounts that, with additions from estimated future premiums received and with interest on such reserves at estimated future rates, are expected to be sufficient to meet our obligations under the terms of the policy. Liabilities for future policy benefits are computed on a net-level premium method based upon assumptions as to future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses determined when the policies were issued (or with respect to policies inforce at August 31, 2003, the Company's best estimate of such assumptions on the Effective Date). We make an additional provision to allow for potential adverse deviation for some of our assumptions. Once established, assumptions on these products are generally not changed unless a premium deficiency exists. In that case, a premium deficiency reserve is recognized and the future pattern of reserve changes is modified to reflect the relationship of premiums to benefits based on the current best estimate of future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses, determined without an additional provision for potential adverse deviation.

We establish claim reserves based on our estimate of the loss to be incurred on reported claims plus estimates of incurred but unreported claims based on our past experience.
Accounting for Long-term Care Premium Rate Increases

Many of our long-term care policies have been subject to premium rate increases. In some cases, these premium rate increases were materially consistent with the assumptions we used to value the particular block of business at the Effective Date. With respect to certain premium rate increases, some of our policyholders were provided an option to cease paying their premiums and receive a non-forfeiture option in the form of a paid-up policy with limited benefits. In addition, our policyholders could choose to reduce their coverage amounts and premiums in the same proportion, when permitted by our contracts or as required by regulators. The following describes how we account for these policyholder options:

Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.

Benefit reductions - A policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.

Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.

Some of our policyholders may receive a non-forfeiture benefit if they cease paying their premiums pursuant to their original contract (or pursuant to changes made to their original contract as a result of a litigation settlement made prior to the Effective Date or an order issued by the Florida Office of Insurance Regulation). In these cases, exercise of this option is treated as the exercise of a policy benefit, and the reserve for premium paying benefits is reduced, and the reserve for the non-forfeiture benefit is adjusted to reflect the election of this benefit.
Accounting for Certain Marketing Agreements

Bankers Life has entered into various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute prescription drug and Medicare Advantage plans. These agreements allow Bankers Life to offer these products to current and potential future policyholders without investment in management and infrastructure. We receive fee income related to the plans sold through our distribution channels and incur distribution expenses paid to our agents who sell such products. As further discussed below under the caption "Recently Issued Accounting Standards - Adopted Accounting Standards", we adopted the new revenue recognition guidance which was effective January 1, 2018. The adoption of this new guidance had no impact on the fee revenue we recognized in any calendar year, but did impact the amounts we recognized during each quarterly period within a calendar year.
Reinsurance

In the normal course of business, we seek to limit our loss exposure on any single insured or to certain groups of policies by ceding reinsurance to other insurance enterprises. We currently retain no more than $.8 million of mortality risk on any one policy. We diversify the risk of reinsurance loss by using a number of reinsurers that have strong claims-paying ratings. In each case, the ceding CNO subsidiary is directly liable for claims reinsured in the event the assuming company is unable to pay.

The cost of reinsurance ceded totaled $144.5 million, $105.0 million and $123.9 million in 2018, 2017 and 2016, respectively.  We deduct this cost from insurance policy income.  Reinsurance recoveries netted against insurance policy benefits totaled $173.5 million, $88.6 million and $130.1 million in 2018, 2017 and 2016, respectively.

From time to time, we assume insurance from other companies.  Any costs associated with the assumption of insurance are amortized consistent with the method used to amortize deferred acquisition costs.  Reinsurance premiums assumed totaled $28.0 million, $30.4 million and $34.0 million in 2018, 2017 and 2016, respectively. Insurance policy benefits related to reinsurance assumed totaled $36.4 million, $44.7 million and $47.5 million in 2018, 2017 and 2016, respectively.

On September 27, 2018, the Company completed a long-term care reinsurance transaction pursuant to which its wholly-owned subsidiary, Bankers Life, entered into an agreement with Wilton Re to cede all of its legacy (prior to 2003) comprehensive and nursing home long-term care policies (with statutory reserves of $2.7 billion) through 100% indemnity coinsurance. Bankers Life paid a ceding commission of $825 million to reinsure the block, funded through excess capital in the insurance subsidiaries and at the holding company. Bankers Life transferred to Wilton Re assets equal to the statutory liabilities supporting the block plus the ceding commission (subject to a customary post-closing adjustment). In anticipation of the reinsurance agreement, the Company reorganized its business segments to move the block to be ceded from the "Bankers Life segment" to the "Long-term care in run-off segment" in the third quarter of 2018. Accordingly, the Company evaluates and tests for loss recognition separately for the ceded block included in the "Long-term care in run-off segment". CNO recognized a charge related to the transaction of $661.1 million, net of taxes and gains recognized on the assets transferred to Wilton Re. The charge is primarily attributable to loss recognition on the block due to the ceding commission. Including cash flows related to reinsurance in loss recognition testing is consistent with the Company's past practices and policies.

In addition to the reinsurance agreement, Bankers Life and another CNO subsidiary entered into certain other agreements with Wilton Re, including a trust agreement, an administrative services agreement and a transition services agreement.

Wilton Re established a trust account for the benefit of Bankers Life to secure its obligations under the coinsurance agreement. The trust account is required to hold qualified assets with book values equal to the statutory liabilities of the block plus an additional amount, initially $500 million, which declines over time.

In December 2013, two of our insurance subsidiaries entered into 100% coinsurance agreements ceding $495 million of long-term care reserves to Beechwood Re Ltd. ("BRe"). Pursuant to the agreements, the insurance subsidiaries paid an additional premium of $96.9 million to BRe and an amount equal to the related net liabilities. The insurance subsidiaries' ceded reserve credits were secured by assets in market-value trusts subject to a 7% overcollateralization, investment guidelines and periodic true-up provisions. Future payments into the trusts to maintain collateral requirements were the responsibility of BRe.

In September 2016, we terminated the reinsurance agreements with BRe and recaptured the ceded business. As a result of the recapture, we were required to value the assets and liabilities as of the date of recapture based on valuation methodologies that are consistent with the methodologies used by CNO to value its other investments and insurance liabilities. Accordingly, we recognized a loss on the recapture of the long-term care business as summarized below (dollars in millions):

Market value of investments
$
504.7

Insurance liabilities
(552.2
)
Write-off of reinsurance receivables
(17.9
)
Estimated transaction expenses
(10.0
)
Pre-tax loss
(75.4
)
Tax benefit
26.4

Increase in valuation allowance for deferred tax assets
(4.1
)
After-tax loss
$
(53.1
)
Income Taxes

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and net operating loss carryforwards ("NOLs"). Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted.

A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred tax assets depends upon generating sufficient future taxable income of the appropriate type during the periods in which our temporary differences become deductible and before our NOLs expire.

At December 31, 2018, our valuation allowance for our net deferred tax assets was $193.7 million, as we have determined that it is more likely than not that a portion of our deferred tax assets will not be realized. This determination was made by evaluating each component of the deferred tax assets and assessing the effects of limitations and/or interpretations on the value of such component to be fully recognized in the future.
Investments in Variable Interest Entities

We have concluded that we are the primary beneficiary with respect to certain variable interest entities ("VIEs"), which are consolidated in our financial statements. All of the VIEs are collateralized loan trusts that were established to issue securities to finance the purchase of corporate loans and other permitted investments.  The assets held by the trusts are legally isolated and not available to the Company.  The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company.  The Company has no financial obligation to the VIEs beyond its investment in each VIE.

The investment portfolios held by the VIEs are primarily comprised of commercial bank loans to corporate obligors which are almost entirely rated below-investment grade.  Refer to the note to the consolidated financial statements entitled "Investments in Variable Interest Entities" for additional information about VIEs.

In addition, the Company, in the normal course of business, makes passive investments in structured securities issued by VIEs for which the Company is not the investment manager.  These structured securities include asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, residential mortgage-backed securities and collateralized mortgage obligations.  Our maximum exposure to loss on these securities is limited to our cost basis in the investment.  We have determined that we are not the primary beneficiary of these structured securities due to the relative size of our investment in comparison to the total principal amount of the individual structured securities and the level of credit subordination which reduces our obligation to absorb gains or losses.

At December 31, 2018, we held investments in various limited partnerships and hedge funds, in which we are not the primary beneficiary, totaling $507.3 million (classified as other invested assets).  At December 31, 2018, we had unfunded commitments to these partnerships and hedge funds totaling $183.8 million.  Our maximum exposure to loss on these investments is limited to the amount of our investment.
Investment borrowings

Three of the Company's insurance subsidiaries (Washington National, Bankers Life and Colonial Penn) are members of the FHLB.  As members of the FHLB, our insurance subsidiaries have the ability to borrow on a collateralized basis from the FHLB.  We are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings.  New guidance effective January 1, 2018, requiring equity investments to be measured at fair value (as described in the section of this note entitled "Recently Issued Accounting Standards - Adopted Accounting Standards") does not apply to FHLB common stock and prohibits such investments from being classified as equity securities subject to the new guidance. Accordingly, we have classified our investment in the FHLB common stock as other invested assets. In order to conform to the current presentation, the prior period investment in the FHLB common stock has been reclassified to other invested assets. At December 31, 2018, the carrying value of the FHLB common stock was $71.1 million.  As of December 31, 2018, collateralized borrowings from the FHLB totaled $1.6 billion and the proceeds were used to purchase fixed maturity securities.  The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet.  The borrowings are collateralized by investments with an estimated fair value of $1.9 billion at December 31, 2018, which are maintained in a custodial account for the benefit of the FHLB.  Substantially all of such investments are classified as fixed maturities, available for sale, in our consolidated balance sheet.

The following summarizes the terms of the borrowings from the FHLB by our insurance subsidiaries (dollars in millions):

Amount
 
Maturity
 
Interest rate at
borrowed
 
date
 
December 31, 2018
$
50.0

 
February 2019
 
Variable rate – 2.719%
21.8

 
July 2019
 
Variable rate – 2.969%
15.0

 
October 2019
 
Variable rate – 3.022%
50.0

 
May 2020
 
Variable rate – 2.975%
21.8

 
June 2020
 
Fixed rate – 1.960%
25.0

 
September 2020
 
Variable rate – 3.449%
100.0

 
September 2020
 
Variable rate – 3.166%
50.0

 
September 2020
 
Variable rate – 3.166%
75.0

 
September 2020
 
Variable rate – 2.923%
100.0

 
October 2020
 
Variable rate – 2.518%
50.0

 
December 2020
 
Variable rate – 3.047%
100.0

 
July 2021
 
Variable rate – 2.986%
100.0

 
July 2021
 
Variable rate – 2.956%
57.7

 
August 2021
 
Variable rate – 3.112%
28.2

 
August 2021
 
Fixed rate – 2.550%
125.0

 
August 2021
 
Variable rate – 2.986%
50.0

 
September 2021
 
Variable rate – 3.229%
22.0

 
May 2022
 
Variable rate – 3.057%
100.0

 
May 2022
 
Variable rate – 2.952%
10.0

 
June 2022
 
Variable rate – 3.381%
50.0

 
July 2022
 
Variable rate – 2.790%
50.0

 
July 2022
 
Variable rate – 2.867%
50.0

 
July 2022
 
Variable rate – 2.889%
50.0

 
August 2022
 
Variable rate – 2.979%
50.0

 
December 2022
 
Variable rate – 3.038%
50.0

 
December 2022
 
Variable rate – 3.038%
23.9

 
March 2023
 
Fixed rate – 2.160%
50.0

 
July 2023
 
Variable rate – 2.845%
100.0

 
July 2023
 
Variable rate – 2.845%
20.4

 
June 2025
 
Fixed rate – 2.940%
$
1,645.8

 
 
 
 


The variable rate borrowings are pre-payable on each interest reset date without penalty.  The fixed rate borrowings are pre-payable subject to payment of a yield maintenance fee based on prevailing market interest rates.  At December 31, 2018, the aggregate yield maintenance fee to prepay all fixed rate borrowings was $.1 million.

Interest expense of $41.9 million, $27.0 million and $17.5 million in 2018, 2017 and 2016, respectively, was recognized related to total borrowings from the FHLB.
Accounting for Derivatives

Our fixed index annuity products provide a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the Standard & Poor's 500 Index, over a specified period.  Typically, on each policy anniversary date, a new index period begins.  We are generally able to change the participation rate at the beginning of each index period during a policy year, subject to policy minimums.  The Company accounts for the options attributed to the policyholder for the estimated life of the policy as embedded derivatives. We are required to record the embedded derivatives related to our fixed index annuity products at estimated fair value.

The value of the embedded derivative is based on the estimated cost to fulfill our commitment to fixed indexed annuity policyholders to purchase a series of annual forward options over the duration of the policy that back the potential return based on a percentage of the amount of increase in the value of the appropriate index. In valuing these options, we are required to make assumptions regarding: (i) future index values to determine both the future notional amounts at each anniversary date and the future prices of the forward starting options; (ii) future annual participation rates; and (iii) non-economic factors related to policy persistency. These assumptions are used to estimate the future cost to purchase the options.

The value of the embedded derivatives is determined based on the present value of estimated future option costs discounted using a risk-free rate adjusted for our non-performance risk and risk margins for non-capital market inputs. The non-performance risk adjustment is determined by taking into consideration publicly available information related to spreads in the secondary market for debt with credit ratings similar to ours. These observable spreads are then adjusted to reflect the priority of these liabilities and the claim paying ability of the issuing insurance subsidiaries.

Risk margins are established to capture non-capital market risks which represent the additional compensation a market participant would require to assume the risks related to the uncertainties regarding the embedded derivatives, including future policyholder behavior related to persistency. The determination of the risk margin is highly judgmental given the lack of a market to assume the risks solely related to the embedded derivatives of our fixed index annuity products.

The determination of the appropriate risk-free rate and non-performance risk is sensitive to the economic and interest rate environment. Accordingly, the value of the derivative is volatile due to external market sensitivities, which may materially affect net income. Additionally, changes in the judgmental assumptions regarding the appropriate risk margin can significantly impact the value of the derivative.

We typically buy call options (including call spreads) referenced to the applicable indices in an effort to offset or hedge potential increases to policyholder benefits resulting from increases in the particular index to which the policy's return is linked.

We purchase certain fixed maturity securities that contain embedded derivatives that are required to be held at fair value on the consolidated balance sheet. We have elected the fair value option to carry the entire security at fair value with changes in fair value reported in net income.
Sales Inducements

Certain of our annuity products offer sales inducements to contract holders in the form of enhanced crediting rates or bonus payments in the initial period of the contract.  Certain of our life insurance products offer persistency bonuses credited to the contract holder's balance after the policy has been outstanding for a specified period of time.  These enhanced rates and persistency bonuses are considered sales inducements in accordance with GAAP.  Such amounts are deferred and amortized in the same manner as deferred acquisition costs.  Sales inducements deferred totaled $11.6 million, $2.0 million and $3.4 million during 2018, 2017 and 2016, respectively.  Amounts amortized totaled $10.6 million, $8.9 million and $11.4 million during 2018, 2017 and 2016, respectively.  The unamortized balance of deferred sales inducements was $43.5 million and $42.5 million at December 31, 2018 and 2017, respectively.
Out-of-Period Adjustments

In 2018, we recorded the net effect of out-of-period adjustments related to the calculation of certain insurance liabilities which increased insurance policy benefits by $2.5 million (of which, $1.4 million related to long-term care reserves in the Bankers Life segment and $1.1 million related to a closed block of payout annuities in the Colonial Penn segment), decreased tax expense by $.5 million and increased our net loss by $2.0 million (or 1 cent per diluted share). In 2017, we recorded the net effect of out-of-period adjustments which decreased insurance policy benefits by $4.2 million, increased other operating costs and expenses by $2.0 million, increased tax expense by $.8 million and increased our net income by $1.4 million (or 1 cent per diluted share). We evaluated these adjustments taking into account both qualitative and quantitative factors and considered the impact of these adjustments in relation to each period, as well as the periods in which they originated. The impact of recognizing these adjustments in prior years was not significant to any individual period. Management believes these adjustments are immaterial to the consolidated financial statements and all previously issued financial statements.
Recently Issued Accounting Standards

Pending Accounting Standards

In February 2016, the Financial Accounting Standards Board (the "FASB") issued authoritative guidance related to accounting for leases, requiring lessees to report most leases on their balance sheets, regardless of whether the lease is classified as a finance lease or an operating lease. For lessees, the initial lease liability is equal to the present value of future lease payments, and a corresponding asset, adjusted for certain items, is also recorded. Expense recognition for lessees will remain similar to current accounting requirements for capital and operating leases. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Based on lease contracts in effect at December 31, 2018, the Company's analysis currently indicates that the primary impact of implementation of the new leasing guidance will be the recognition of a "right to use" asset and a "lease liability" of approximately $65 million. The cumulative effect adjustment to retained earnings as of January 1, 2019 is not material.

In June 2016, the FASB issued authoritative guidance related to the measurement of credit losses on financial instruments. The new guidance replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The guidance will be effective for the Company for fiscal years beginning in 2020, including interim periods within the fiscal year. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows.

In January 2017, the FASB issued authoritative guidance that removes Step 2 of the goodwill impairment test under current guidance, which requires a hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reported unit's fair value. Upon adoption, the guidance is to be applied prospectively. The guidance will be effective for the Company on January 1, 2020, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations or cash flows.

In March 2017, the FASB issued authoritative guidance related to the premium amortization on purchased callable debt securities. The guidance shortens the amortization period for certain callable debt securities held at a premium. Specifically, the new guidance requires the premium to be amortized to the earliest call date. The guidance does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The guidance will be effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations or cash flows based on the investments held by the Company at December 31, 2018, that are applicable to this guidance.

In August 2017, the FASB issued authoritative guidance related to derivatives and hedging. The new guidance expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instruments and the hedged item in the financial statements. The new guidance also includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Based on the Company's current use of derivatives and hedging activities, the adoption of this guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations or cash flows.

In August 2018, the FASB issued authoritative guidance that will result in significant changes in the manner we account for and report our insurance contracts, including certain contract riders and deferred acquisition costs. The effective date is January 1, 2021.

The significant provisions of the new standard and differences from current methods are summarized below:

Under the current standard, liabilities for future policy benefits for long-duration products are established based on assumptions set at the issue date which are not changed unless there is a premium deficiency. Under the new standard, mortality, morbidity, persistency and expense assumptions must be reviewed for potential changes at least annually. For these assumption changes, the liability for future policy benefits is recomputed and a cumulative catch-up adjustment is recorded in current year income. The interest rate used to discount future cash flows will be based on the current yield of an upper-medium grade fixed income instrument and must be updated each reporting period; changes in the liability resulting from interest rate changes are recorded in accumulated other comprehensive income. Under current methods, the interest rate is based on expected yields on the underlying investment portfolio estimated at the issue date.

We will no longer be permitted to include a provision for adverse deviation in calculations of the liability for future policy benefits.

Since assumptions are updated regularly, there is no longer a need for premium deficiency testing.

The new guidance introduces the concept of market risk benefits for product features such as guaranteed minimum death or income benefits, which must be accounted for at fair value.

Deferred acquisition costs will generally be amortized on a constant level basis over the expected term of the contracts. Amortization based on estimated gross profits or gross margins will no longer be permitted. Deferred acquisition costs will no longer need to be tested for impairment and no interest is accreted. Adjustments for the change in amortization that would have occurred if fixed maturity securities, available for sale, had been sold at their aggregate fair value and the proceeds reinvested at current yields (commonly referred to as "shadow adjustments") will no longer be required.

Significant additional annual and interim disclosures will be required including requirements for disaggregated rollforwards of the liability for future policy benefits, policyholder account balances, market risk benefits and deferred acquisition costs, as well as qualitative and quantitative information about expected cash flows, estimates and assumptions.

The new guidance is generally required to be adopted on a modified retrospective transition approach, with an option to elect a full retrospective transition if certain criteria are met. The transition approach for deferred acquisition costs is required to be consistent with the transition applied to the liability for future policyholder benefits. Under the modified retrospective approach, an entity would continue to use the existing locked-in investment yield interest rate assumption to calculate the net premium ratio for contracts in-force at the transition date. However, for balance sheet remeasurement purposes, the current upper-medium grade fixed-income corporate instrument yield would be used with the difference in values recognized through accumulated other comprehensive income at transition and subsequently through other comprehensive income. For market risk benefits, retrospective application is required, with the ability to use hindsight to measure fair value components to the extent assumptions in a prior period are unobservable or otherwise unavailable. We are currently in the early stages of implementing our project plan with respect to the new standard. Accordingly, we are continuing to evaluate the impact of adopting this new standard on our consolidated financial condition and results of operations.

In August 2018, the FASB issued authoritative guidance related to changes to the disclosure requirements for fair value measurement. The new guidance removes, modifies and adds certain disclosure requirements. The guidance will be effective for the Company on January 1, 2020. The adoption of such guidance will impact certain fair value disclosures, but will not impact our consolidated financial position, results of operations or cash flows.

Adopted Accounting Standards

In May 2014, the FASB issued authoritative guidance for recognizing revenue from contracts with customers. Certain contracts with customers are specifically excluded from this guidance, including insurance contracts. The core principle of the new guidance is that an entity should recognize revenue when it transfers promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance was effective for the Company on January 1, 2018. The adoption of this new guidance impacted the timing of certain revenues and expenses between quarters of a calendar year for various distribution and marketing agreements with other insurance companies pursuant to which Bankers Life's career agents distribute third party products including prescription drug and Medicare Advantage plans. The annual fee income earned during a calendar year did not change, but the amount recognized during each quarterly period varied based on the sales of such products in each period. Furthermore, we recognized distribution expenses in the same period that the associated fee revenue was earned. Periods prior to the January 1, 2018 adoption date were not restated to reflect the new guidance.

In January 2016, the FASB issued authoritative guidance related to the recognition and measurement of financial assets and financial liabilities which made targeted improvements to GAAP as follows:

(i)
Require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
(ii)
Simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value.
(iii)
Eliminate the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet.
(iv)
Require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes.
(v)
Require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments.
(vi)
Require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements.
(vii)
Clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity's other deferred tax assets.

The guidance was effective for the Company on January 1, 2018. Accordingly, the Company recorded a cumulative effect adjustment to the balance sheet as of January 1, 2018, related to certain equity investments that are measured at fair value. The impact of adoption was as follows (dollars in millions):
 
January 1, 2018
 
Amounts prior to effect of adoption of authoritative guidance
 
Effect of adoption of authoritative guidance
 
As adjusted
 
 
 
 
 
 
Accumulated other comprehensive income
$
1,212.1

 
$
(16.3
)
 
$
1,195.8

Retained earnings
560.4

 
16.3

 
576.7

Total shareholders' equity
4,847.5

 

 
4,847.5


In August 2016, the FASB issued authoritative guidance related to how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues including debt prepayment or debt extinguishment costs, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, and others. The guidance was effective for the Company on January 1, 2018. The adoption of this guidance resulted in reclassifications to certain cash receipts and payments within our consolidated statement of cash flows, but had no impact on our consolidated financial position, results of operations or cash flows. Periods prior to the January 1, 2018 adoption date have been restated to reflect the new guidance.

In November 2016, the FASB issued authoritative guidance to address the diversity in practice that currently exists regarding the classification and presentation of changes in restricted cash on the statement of cash flows. The new guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. Entities are also required to disclose information about the nature of their restricted cash and restricted cash equivalents. Additionally, if cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item in the statement of financial position, entities will be required to present a reconciliation, either on the face of the statement of cash flows or disclosed in the notes, of the totals in the statement of cash flows to the related line item captions in the statement of financial position. The guidance was effective for the Company on January 1, 2018. The adoption of this guidance impacted the presentation of our consolidated statement of cash flows and related cash flow disclosures, but did not have an impact on our consolidated financial position, results of operations or cash flows. Periods prior to the January 1, 2018 adoption date have been restated to reflect the new guidance.
The impact of adopting the cash flow guidance described above was as follows (dollars in millions):

 
2017
 
Amounts prior to effect of adoption of authoritative guidance
 
Restricted cash
 
COLI death benefits
 
Distributions received from equity method investments
 
As adjusted
Cash flows from operating activities:
 
 
 
 
 
 
 
 
 
Net investment income
$
1,229.6

 
$

 
$

 
$
26.7

 
$
1,256.3

Other operating costs
(740.9
)
 

 
(6.5
)
 

 
(747.4
)
Net cash flow from operating activities
613.1

 

 
(6.5
)
 
26.7

 
633.3

 
 
 
 
 
 
 
 
 
 
Cash flows from investing activities:
 
 
 
 
 
 
 
 
 
Sales of investments
2,487.4

 

 

 
(26.7
)
 
2,460.7

Change in cash and cash equivalents held by variable interest entities
10.4

 
(10.4
)
 

 

 

Other
(29.9
)
 

 
6.5

 

 
(23.4
)
Net cash provided (used) by investing activities
(239.6
)
 
(10.4
)
 
6.5

 
(26.7
)
 
(270.2
)
 
 
 
 
 
 
 
 
 
 
Net increase (decrease) in cash and cash equivalents
99.5

 
(10.4
)
 

 

 
89.1

Cash and cash equivalents - unrestricted and held by variable interest entities, beginning of period
478.9

 
189.3

 

 

 
668.2

Cash and cash equivalents - unrestricted and held by variable interest entities, end of period
578.4

 
178.9

 

 

 
757.3



 
2016
 
Amounts prior to effect of adoption of authoritative guidance
 
Restricted cash
 
Distributions received from equity method investments
 
As adjusted
Cash flows from operating activities:
 
 
 
 
 
 
 
Net investment income
$
1,201.0

 
$

 
$
12.9

 
$
1,213.9

Net cash flow from operating activities
762.8

 

 
12.9

 
775.7

 
 
 
 
 
 
 
 
Cash flows from investing activities:
 
 
 
 
 
 
 
Sales of investments
2,841.8

 

 
(12.9
)
 
2,828.9

Change in cash and cash equivalents held by variable interest entities
175.1

 
(175.1
)
 

 

Net cash provided (used) by investing activities
(742.4
)
 
(175.1
)
 
(12.9
)
 
(930.4
)
 
 
 
 
 
 
 
 
Net increase (decrease) in cash and cash equivalents
46.6

 
(175.1
)
 

 
(128.5
)
Cash and cash equivalents - unrestricted and held by variable interest entities, beginning of period
432.3

 
364.4

 

 
796.7

Cash and cash equivalents - unrestricted and held by variable interest entities, end of period
478.9

 
189.3

 

 
668.2



In May 2017, the FASB issued authoritative guidance related to which changes to the terms or conditions of a share-based award require an entity to apply modification accounting. The guidance was effective for the Company for fiscal years beginning after December 15, 2017. Early adoption was permitted, including adoption in an interim period. The guidance is to be applied prospectively to an award modified on or after the adoption date. The adoption of this guidance did not have a material impact to the Company's consolidated financial position, results of operations or cash flows.

In March 2016, the FASB issued authoritative guidance that clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under this guidance is required to assess the embedded call (put) options solely in accordance with a four-step decision sequence. The guidance was effective for the Company on January 1, 2017. The adoption of this guidance had no effect on our consolidated financial statements.
In March 2016, the FASB issued authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting policy for forfeiture rate assumptions, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new guidance requires all income tax effects of stock-based compensation awards to be recognized in the income statement when the awards vest or are settled. The new guidance also allows an employer to withhold shares upon settlement of an award to satisfy the employer's tax withholding requirements up to the highest marginal tax rate applicable to employees, without resulting in liability classification of the award. Current guidance strictly limits the withholding to the employer's minimum statutory tax withholding requirement. The guidance was effective for the Company on January 1, 2017. The impact of adoption was as follows (dollars in millions):
 
January 1, 2017
 
 
 
Effect of Adoption of Authoritative Guidance
 
 
 
Amounts prior to effect of adoption of authoritative guidance
 
Election to account for forfeitures as they occur
 
Recognition of excess tax benefits
 
As adjusted
 
 
 
 
 
 
 
 
Income tax assets
$
1,029.9

 
$
.3

 
$
15.7

 
$
1,045.9

Valuation allowance for deferred income tax assets
(240.2
)
 

 
(15.7
)
 
(255.9
)
Income tax assets, net
789.7

 
.3

 

 
790.0

Total assets
31,975.2

 
.3

 

 
31,975.5

 
 
 
 
 
 
 
 
Additional paid-in capital
3,212.1

 
.9

 

 
3,213.0

Retained earnings
650.7

 
(.6
)
 

 
650.1

Total shareholders' equity
4,486.9

 
.3

 

 
4,487.2

 
 
 
 
 
 
 
 
Total liabilities and shareholders' equity
31,975.2

 
.3

 

 
31,975.5


In October 2016, the FASB issued authoritative guidance to amend the consolidation guidance on how a reporting entity that is the single decision maker of a VIE should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The guidance was effective for the Company on January 1, 2017. The adoption of this guidance had no impact on our consolidated financial statements.

In February 2018, the FASB issued authoritative guidance that allows a reclassification from accumulated other comprehensive income to retained earnings for the stranded tax effects resulting from the Tax Cuts and Jobs Act (the "Tax Reform Act") enacted by the U.S. federal government on December 22, 2017. Such guidance only relates to the reclassification of the income tax effects of the Tax Reform Act. The Company early adopted this guidance and elected to reclassify the income tax effects of the Tax Reform Act from accumulated other comprehensive income as of December 31, 2017. As a result of such reclassification, retained earnings decreased by $205.4 million and accumulated other comprehensive income increased by $205.4 million. Such amount represents the decrease in the income tax rate from 35 percent to 21 percent on the net unrealized gains of our fixed maturity securities, available for sale, equity securities and certain other invested assets, net of related adjustments, included in accumulated other comprehensive income. Refer to the note to the consolidated financial statements entitled "Income Taxes" for additional information related to the Tax Reform Act.
v3.10.0.1
INVESTMENTS
12 Months Ended
Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]  
INVESTMENTS
INVESTMENTS

At December 31, 2018, the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, were as follows (dollars in millions):

 
Amortized
cost
 
Gross
unrealized
gains
 
Gross
unrealized
losses
 
Estimated
fair
value
 
Other-than-temporary impairments included in accumulated other comprehensive income
Investment grade (a):
 
 
 
 
 
 
 
 
 
Corporate securities
$
10,306.1

 
$
402.4

 
$
(319.2
)
 
$
10,389.3

 
$

United States Treasury securities and obligations of United States government corporations and agencies
152.9

 
22.1

 
(.2
)
 
174.8

 

States and political subdivisions
1,725.8

 
144.6

 
(2.6
)
 
1,867.8

 

Debt securities issued by foreign governments
60.3

 
.9

 
(1.7
)
 
59.5

 

Asset-backed securities
1,513.2

 
21.9

 
(6.7
)
 
1,528.4

 

Collateralized debt obligations
325.3

 

 
(13.5
)
 
311.8

 

Commercial mortgage-backed securities
1,445.0

 
16.6

 
(20.4
)
 
1,441.2

 

Mortgage pass-through securities
1.5

 
.1

 

 
1.6

 

Collateralized mortgage obligations
347.6

 
11.4

 
(3.9
)
 
355.1

 
(.2
)
Total investment grade fixed maturities, available for sale
15,877.7

 
620.0

 
(368.2
)
 
16,129.5

 
(.2
)
Below-investment grade (a) (b):
 

 
 

 
 

 
 

 
 
Corporate securities
862.4

 
2.3

 
(51.0
)
 
813.7

 

Asset-backed securities
1,038.9

 
108.4

 
(.9
)
 
1,146.4

 

Collateralized debt obligations
12.7

 

 
(1.7
)
 
11.0

 

Commercial mortgage-backed securities
77.9

 
.2

 
(1.3
)
 
76.8

 

Collateralized mortgage obligations
238.2

 
32.3

 
(.2
)
 
270.3

 
(.3
)
Total below-investment grade fixed maturities, available for sale
2,230.1

 
143.2

 
(55.1
)
 
2,318.2

 
(.3
)
Total fixed maturities, available for sale
$
18,107.8

 
$
763.2

 
$
(423.3
)
 
$
18,447.7

 
$
(.5
)
_______________
(a)
Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody's Investor Services, Inc. ("Moody's"), S&P Global Ratings ("S&P") or Fitch Ratings ("Fitch")), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC").  NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by S&P and Fitch).  NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch).  References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above.
(b)
Certain structured securities rated below-investment grade by NRSROs may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the NAIC. Refer to the table below for a summary of our fixed maturity securities, available for sale, by NAIC designations.

The NAIC evaluates the fixed maturity investments of insurers for regulatory and capital assessment purposes and assigns securities to one of six credit quality categories called NAIC designations, which are used by insurers when preparing their annual statements based on statutory accounting principles. The NAIC designations are generally similar to the credit quality designations of the NRSROs for marketable fixed maturity securities, except for certain structured securities. However, certain structured securities rated below investment grade by the NRSROs can be assigned NAIC 1 or NAIC 2 designations depending on the cost basis of the holding relative to estimated recoverable amounts as determined by the NAIC. The following summarizes the NAIC designations and NRSRO equivalent ratings:

NAIC Designation
 
NRSRO Equivalent Rating
1
 
AAA/AA/A
2
 
BBB
3
 
BB
4
 
B
5
 
CCC and lower
6
 
In or near default



A summary of our fixed maturity securities, available for sale, by NAIC designations (or for fixed maturity securities held by non-regulated entities, based on NRSRO ratings) as of December 31, 2018 is as follows (dollars in millions):

NAIC designation
 
Amortized cost
 
Estimated fair value
 
Percentage of total estimated fair value
1
 
$
8,836.9

 
$
9,311.7

 
50.5
%
2
 
8,353.6

 
8,270.0

 
44.8

Total NAIC 1 and 2 (investment grade)
 
17,190.5

 
17,581.7

 
95.3

3
 
674.1

 
641.4

 
3.5

4
 
218.0

 
200.3

 
1.1

5
 
19.7

 
18.9

 
.1

6
 
5.5

 
5.4

 

Total NAIC 3,4,5 and 6 (below-investment grade)
 
917.3

 
866.0

 
4.7

 
 
$
18,107.8

 
$
18,447.7

 
100.0
%


At December 31, 2017, the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions):

 
Amortized
cost
 
Gross
unrealized
gains
 
Gross
unrealized
losses
 
Estimated
fair
value
 
Other-than-temporary impairments included in accumulated other comprehensive income
Investment grade:
 
 
 
 
 
 
 
 
 
Corporate securities
$
12,419.3

 
$
1,670.7

 
$
(14.6
)
 
$
14,075.4

 
$

United States Treasury securities and obligations of United States government corporations and agencies
146.4

 
31.5

 
(.2
)
 
177.7

 

States and political subdivisions
1,819.9

 
234.8

 
(.4
)
 
2,054.3

 

Debt securities issued by foreign governments
79.5

 
3.8

 
(.2
)
 
83.1

 

Asset-backed securities
1,730.7

 
39.7

 
(3.2
)
 
1,767.2

 

Collateralized debt obligations
257.1

 
2.3

 

 
259.4

 

Commercial mortgage-backed securities
1,304.1

 
33.2

 
(9.1
)
 
1,328.2

 

Mortgage pass-through securities
1.8

 
.2

 

 
2.0

 

Collateralized mortgage obligations
293.9

 
16.4

 
(.2
)
 
310.1

 
(.2
)
Total investment grade fixed maturities, available for sale
18,052.7

 
2,032.6

 
(27.9
)
 
20,057.4

 
(.2
)
Below-investment grade:
 

 
 

 
 

 
 

 
 
Corporate securities
867.0

 
28.4

 
(12.4
)
 
883.0

 

States and political subdivisions
2.0

 

 

 
2.0

 

Asset-backed securities
1,355.2

 
132.9

 
(.9
)
 
1,487.2

 

Commercial mortgage-backed securities
49.9

 
.6

 
(1.2
)
 
49.3

 

Collateralized mortgage obligations
375.3

 
56.8

 
(.1
)
 
432.0

 
(.8
)
Total below-investment grade fixed maturities, available for sale
2,649.4

 
218.7

 
(14.6
)
 
2,853.5

 
(.8
)
Total fixed maturities, available for sale
$
20,702.1

 
$
2,251.3

 
$
(42.5
)
 
$
22,910.9

 
$
(1.0
)
Equity securities
$
420.0

 
$
23.6

 
$
(3.0
)
 
$
440.6

 
 


Accumulated other comprehensive income is primarily comprised of the net effect of unrealized appreciation (depreciation) on our investments.  These amounts, included in shareholders' equity as of December 31, 2018 and 2017, were as follows (dollars in millions):

 
2018
 
2017
Net unrealized appreciation on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized
$
1.2

 
$
2.6

Net unrealized gains on all other investments
271.3

 
2,227.3

Adjustment to present value of future profits (a)
(4.5
)
 
(94.0
)
Adjustment to deferred acquisition costs
(38.3
)
 
(292.6
)
Adjustment to insurance liabilities
(2.5
)
 
(295.8
)
Deferred income tax liabilities
(49.5
)
 
(335.4
)
Accumulated other comprehensive income
$
177.7

 
$
1,212.1

________
(a)
The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003, the date our Predecessor emerged from bankruptcy.

At December 31, 2018, adjustments to the insurance liabilities and deferred tax assets included $(2.5) million and $.5 million, respectively, for premium deficiencies that would exist on certain blocks of business if unrealized gains on the assets backing such products had been realized and the proceeds from the sales of such assets were invested at then current yields.

At December 31, 2017, adjustments to the present value of future profits, deferred acquisition costs, insurance liabilities and deferred tax assets included $(83.8) million, $(134.9) million, $(295.8) million and $111.1 million, respectively, for premium deficiencies that would exist on certain blocks of business (primarily long-term care products) if unrealized gains on the assets backing such products had been realized and the proceeds from the sales of such assets were invested at then current yields.

Below-Investment Grade Securities

At December 31, 2018, the amortized cost of the Company's below-investment grade fixed maturity securities was $2,230.1 million, or 12 percent of the Company's fixed maturity portfolio. The estimated fair value of the below-investment grade portfolio was $2,318.2 million, or 104 percent of the amortized cost.

Below-investment grade corporate debt securities typically have different characteristics than investment grade corporate debt securities.  Based on historical performance, probability of default by the borrower is significantly greater for below-investment grade corporate debt securities and in many cases severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer.  Also, issuers of below-investment grade corporate debt securities frequently have higher levels of debt relative to investment-grade issuers, hence, all other things being equal, are generally more sensitive to adverse economic conditions.  The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry.

Contractual Maturity

The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at December 31, 2018, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.  Structured securities (such as asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations, collectively referred to as "structured securities") frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

 
Amortized
cost
 
Estimated
fair
value
 
(Dollars in millions)
Due in one year or less
$
405.6

 
$
409.8

Due after one year through five years
1,346.8

 
1,377.1

Due after five years through ten years
1,648.2

 
1,625.7

Due after ten years
9,706.9

 
9,892.5

Subtotal
13,107.5

 
13,305.1

Structured securities
5,000.3

 
5,142.6

Total fixed maturities, available for sale
$
18,107.8

 
$
18,447.7



Net Investment Income

Net investment income consisted of the following (dollars in millions):

 
2018
 
2017
 
2016
General account assets:
 
 
 
 
 
Fixed maturities
$
1,100.3

 
$
1,133.8

 
$
1,081.4

Equity securities
22.8

 
22.5

 
19.4

Mortgage loans
82.0

 
91.5

 
91.0

Policy loans
8.0

 
7.7

 
7.3

Other invested assets
79.2

 
47.2

 
26.4

Cash and cash equivalents
10.9

 
5.9

 
2.0

Policyholder and other special-purpose portfolios:
 
 
 
 
 
Trading securities (a)
8.5

 
12.8

 
12.2

Options related to fixed index products:
 
 
 
 
 
Option income (loss)
122.3

 
110.3

 
(40.1
)
Change in value of options
(165.3
)
 
52.2

 
69.3

Other special-purpose portfolios
61.0

 
90.6

 
79.7

Gross investment income
1,329.7

 
1,574.5

 
1,348.6

Less investment expenses
23.5

 
23.2

 
23.4

Net investment income
$
1,306.2

 
$
1,551.3

 
$
1,325.2

_________________
(a)
Changes in the estimated fair value for trading securities still held as of the end of the respective years and included in net investment income were nil, $3.8 million and $(.2) million for the years ended December 31, 2018, 2017 and 2016, respectively.

At December 31, 2018, the carrying value of fixed maturities and mortgage loans that were non-income producing during 2018 totaled $4.8 million and $7.8 million, respectively.

Net Realized Investment Gains (Losses)

The following table sets forth the net realized investment gains (losses) for the periods indicated (dollars in millions):

 
2018
 
2017
 
2016
Fixed maturity securities, available for sale:
 
 
 
 
 
Gross realized gains on sale
$
65.7

 
$
68.0

 
$
137.7

Gross realized losses on sale
(65.8
)
 
(24.2
)
 
(95.2
)
Impairments:
 
 
 
 
 
Total other-than-temporary impairment losses
(.5
)
 
(12.5
)
 
(15.2
)
Other-than-temporary impairment losses recognized in accumulated other comprehensive income

 
(.9
)
 
3.6

Net impairment losses recognized
(.5
)
 
(13.4
)
 
(11.6
)
Net realized investment gains (losses) from fixed maturities
(.6
)
 
30.4

 
30.9

Equity securities, including change in fair value (a)
(38.2
)
 
11.6

 
20.9

Mortgage loans
(1.3
)
 
1.1

 

Impairments of other investments
(2.1
)
 
(9.4
)
 
(20.7
)
Loss on dissolution of variable interest entities

 
(4.3
)
 
(7.3
)
Other (a) (b)
30.9

 
20.9

 
(15.5
)
Net realized investment gains (losses) before net realized gains on the transfer of assets related to reinsurance transaction
(11.3
)
 
50.3

 
8.3

Net realized gains on the transfer of assets related to reinsurance transaction
363.4

 

 

Net realized investment gains (losses)
$
352.1

 
$
50.3

 
$
8.3


_________________
(a)
Changes in the estimated fair value of trading securities that we have elected the fair value option and equity securities (and are still held as of the end of the respective years) were $(31.9) million, $12.8 million and $(.5) million for the years ended December 31, 2018, 2017 and 2016, respectively.
(b)
In April 2016, the Company announced that it had invested in a non-controlling minority interest in Tennenbaum Capital Partners, LLC ("TCP"), a Los Angeles-based investment management firm. In August 2018, Blackrock, Inc. announced the completion of its acquisition of TCP. The sale of our interest in TCP resulted in a significant portion of the net realized gains in 2018.

During 2018, we recognized net realized investment gains of $352.1 million, which were comprised of: (i) $40.1 million of net gains from the sales of investments; (ii) $363.4 million of gains on the transfer of assets (substantially all of which were fixed maturities) related to reinsurance transaction; (iii) $38.2 million of losses related to equity securities, including the change in fair value; (iv) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $5.5 million; (v) the decrease in fair value of embedded derivatives related to a modified coinsurance agreement of $5.1 million; and (vi) $2.6 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

During 2017 and 2016, VIEs that were required to be consolidated were dissolved. We recognized losses of $4.3 million and $7.3 million during 2017 and 2016, respectively, representing the difference between the borrowings of such VIEs and the contractual distributions required following the liquidation of the underlying assets.

During 2017, we recognized net realized investment gains of $50.3 million, which were comprised of: (i) $63.1 million of net gains from the sales of investments; (ii) $4.3 million of losses on the dissolution of VIEs; (iii) the increase in fair value of certain fixed maturity investments with embedded derivatives of $11.5 million; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $2.8 million; and (v) $22.8 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

During 2016, we recognized net realized investment gains of $8.3 million, which were comprised of: (i) $47.5 million of net gains from the sales of investments; (ii) a $7.3 million loss on the dissolution of a VIE; (iii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $.4 million; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $.8 million; and (v) $32.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($35.9 million, prior to the $3.6 million of impairment losses recognized through accumulated other comprehensive income).

At December 31, 2018, there were no fixed maturity investments in default.

During 2018, the $65.8 million of realized losses on sales of $1,295.8 million of fixed maturity securities, available for sale, included: (i) $54.0 million related to various corporate securities; (ii) $4.1 million related to commercial mortgage-backed securities; (iii) $4.1 million related to asset-backed securities; and (iv) $3.6 million related to various other investments.  Securities are generally sold at a loss following unforeseen issuer-specific events or conditions or shifts in perceived relative values.  These reasons include but are not limited to: (i) changes in the investment environment; (ii) expectation that the market value could deteriorate; (iii) our desire to reduce our exposure to an asset class, an issuer or an industry; (iv) prospective or actual changes in credit quality; or (v) changes in expected portfolio cash flows.

During 2018, we recognized $2.6 million of impairment losses recorded in earnings which included: (i) $2.1 million related to a mortgage loan due to issuer specific events; and (ii) $.5 million related to a corporate security.

During 2017, the $24.2 million of realized losses on sales of $427.6 million of fixed maturity securities, available for sale included: (i) $16.8 million related to various corporate securities; (ii) $3.6 million related to commercial mortgage-backed securities; and (iii) $3.8 million related to various other investments.

During 2017, we recognized $22.8 million of impairment losses recorded in earnings which included: (i) $6.7 million of writedowns on fixed maturities in the energy sector; (ii) $5.2 million of writedowns related to a mortgage loan; and (iii) $10.9 million of writedowns on other investments. Factors considered in determining the writedowns of investments in 2017 included changes in the estimated recoverable value of the assets related to each investment and the timing of and complexities related to the recovery process.

During 2016, the $95.2 million of realized losses on sales of $790.2 million of fixed maturity securities, available for sale, included: (i) $79.2 million related to various corporate securities (including $63.5 million related to sales of investments in the energy sector); (ii) $5.8 million related to commercial mortgage-backed securities; (iii) $5.7 million related to asset-backed securities; and (iv) $4.5 million related to various other investments.  

During 2016, we recognized $32.3 million of impairment losses recorded in earnings which included: (i) $9.3 million of writedowns on fixed maturities in the energy sector; (ii) $3.7 million of writedowns on a direct loan due to borrower specific events; (iii) $12.7 million of writedowns on a privately placed preferred stock of an entity formed to construct and operate a chemical plant; (iv) $1.2 million of writedowns of investments held by VIEs due to other-than-temporary declines in value; and (v) $5.4 million of losses on other investments. Factors considered in determining the writedowns of investments in 2016 included the subordination status of each investment, the impact of recent downgrades and issuer specific events, including the impact of low oil prices on issuers in the energy sector.

Our fixed maturity investments are generally purchased in the context of various long-term strategies, including funding insurance liabilities, so we do not generally seek to generate short-term realized gains through the purchase and sale of such securities.  In certain circumstances, including those in which securities are selling at prices which exceed our view of their underlying economic value, or when it is possible to reinvest the proceeds to better meet our long-term asset-liability objectives, we may sell certain securities.

The following summarizes the investments sold at a loss during 2018 which had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis prior to the sale for the period indicated (dollars in millions):

 
 
 
At date of sale
 
Number
of issuers
 
Amortized cost
 
Fair value
Less than 6 months prior to sale
5
 
$
56.3

 
$
44.0

Greater than 12 months prior to sale
1
 
.1

 

 
6
 
$
56.4

 
$
44.0



We regularly evaluate all of our investments with unrealized losses for possible impairment.  Our assessment of whether unrealized losses are "other than temporary" requires significant judgment.  Factors considered include: (i) the extent to which fair value is less than the cost basis; (ii) the length of time that the fair value has been less than cost; (iii) whether the unrealized loss is event driven, credit-driven or a result of changes in market interest rates or risk premium; (iv) the near-term prospects for specific events, developments or circumstances likely to affect the value of the investment; (v) the investment's rating and whether the investment is investment-grade and/or has been downgraded since its purchase; (vi) whether the issuer is current on all payments in accordance with the contractual terms of the investment and is expected to meet all of its obligations under the terms of the investment; (vii) whether we intend to sell the investment or it is more likely than not that circumstances will require us to sell the investment before recovery occurs; (viii) the underlying current and prospective asset and enterprise values of the issuer and the extent to which the recoverability of the carrying value of our investment may be affected by changes in such values; (ix) projections of, and unfavorable changes in, cash flows on structured securities including mortgage-backed and asset-backed securities; (x) our best estimate of the value of any collateral; and (xi) other objective and subjective factors.

Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio.  Significant losses could have a material adverse effect on our consolidated financial statements in future periods.

The manner in which impairment losses on fixed maturity securities, available for sale, are recognized in the financial statements is dependent on the facts and circumstances related to the specific security.  If we intend to sell a security or it is more likely than not that we would be required to sell a security before the recovery of its amortized cost, the security is other-than-temporarily impaired and the full amount of the impairment is recognized as a loss through earnings.  If we do not expect to recover the amortized cost basis, we do not plan to sell the security, and if it is not more likely than not that we would be required to sell a security before the recovery of its amortized cost, less any current period credit loss, the recognition of the other-than-temporary impairment is bifurcated.  We recognize the credit loss portion in net income and the noncredit loss portion in accumulated other comprehensive income.

We estimate the amount of the credit loss component of a fixed maturity security impairment as the difference between amortized cost and the present value of the expected cash flows of the security.  The present value is determined using the best estimate of future cash flows discounted at the effective interest rate implicit to the security at the date of purchase or the current yield to accrete an asset-backed or floating-rate security.  The methodology and assumptions for establishing the best estimate of future cash flows vary depending on the type of security.

For most structured securities, cash flow estimates are based on bond-specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including overcollateralization, excess spread, subordination and guarantees.  For corporate bonds, cash flow estimates are derived from scenario-based outcomes of expected corporate restructurings or the disposition of assets using bond-specific facts and circumstances. The previous amortized cost basis less the impairment recognized in net income becomes the security's new cost basis.  We accrete the new cost basis to the estimated future cash flows over the expected remaining life of the security, except when the security is in default or considered nonperforming.

The remaining noncredit impairment, which is recorded in accumulated other comprehensive income, is the difference between the security's estimated fair value and our best estimate of future cash flows discounted at the effective interest rate prior to impairment.  The remaining noncredit impairment typically represents changes in the market interest rates, current market liquidity and risk premiums.  As of December 31, 2018, other-than-temporary impairments included in accumulated other comprehensive income totaled $.5 million (before taxes and related amortization).

Mortgage loans are impaired when it is probable that we will not collect the contractual principal and interest on the loan. We measure impairment based upon the difference between the carrying value of the loan and the estimated fair value of the collateral securing the loan less cost to sell.

The following table summarizes the amount of credit losses recognized in earnings on fixed maturity securities, available for sale, held at the beginning of the period, for which a portion of the other-than-temporary impairment was also recognized in accumulated other comprehensive income for the years ended December 31, 2018, 2017 and 2016 (dollars in millions):

 
Year ended
 
<